Pertuzumab (or biosimilar)
Sponsors
University of Kansas Medical Center, Tianjin Medical University Cancer Institute and Hospital
Conditions
Breast Cancer
Phase 2
Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer
Not yet recruitingNCT07220135
Start: 2025-11-14End: 2031-05-14Target: 100Updated: 2025-10-23
Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer
Not yet recruitingNCT07246317
Start: 2025-12-15End: 2032-12-31Target: 188Updated: 2025-11-28